NCT05510245View on ClinicalTrials.gov

A Clinical Trial of the Study Medicine (PF-07081532) in People With Diabetes and Kidney Dysfunction

PHASE1TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 29, 2022

Primary Completion Date

July 20, 2023

Study Completion Date

July 20, 2023

Conditions
Type 2 DiabetesRenal Impairment
Interventions
DRUG

PF-07081532

One PF-07081532 20 mg tablet, administered orally

Trial Locations (2)

33603

Genesis Clinical Research, LLC, Tampa

55114

Prism Research LLC dba Nucleus Network, Saint Paul

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY